**Trodelvy: New Treatment Options for Breast Cancer**

New Data Highlights sacituzumab Govitecan’s Impact on Survival and Quality of Life in Advanced Breast Cancer

Recent findings reveal that Sacituzumab Govitecan demonstrates a notable improvement in progression-free survival (PFS) and overall survival (OS) for patients with advanced breast cancer compared to standard monochemotherapy. The data also indicates a positive impact on the deterioration of health-related quality of life and fatigue.

Extended Survival and Improved Quality of Life Observed

In a comparative analysis, the Sacituzumab Govitecan group showed notable extensions in key survival metrics:

• Progression-free Survival (PFS): The median PFS was extended by 1.5 months (Hazard Ratio [HR] = 0.661; 95% Confidence Interval [CI] [0.529; 0.826]; p = 0.0003).
• Overall Survival (OS): The median OS was extended by 3.2 months (HR = 0.789; 95% CI [0.646; 0.964]; p = 0.0223).
• time to Deterioration: The time until deterioration was significantly delayed for:
  • Health-related quality of life (HR = 0.751; 95% CI [0.612; 0.922]; p = 0.0059).
  • Fatigue (HR = 0.732; 95% CI [0.598; 0.894]; p = 0.0021).

While Sacituzumab Govitecan demonstrated these benefits, it was associated with a higher incidence of serious adverse events (28%) compared to monochemotherapy (19%), with the majority of these being grade 3. No significant difference was observed in the time to deterioration of pain between the groups. The risk management plan identifies serious infections secondary to neutropenia and severe diarrhea as significant risks associated with Sacituzumab Govitecan.